Cogent Biosciences

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$5,588
Gross Profit
-1,080
-1,066
4,794
EBITDA
-63,307
-61,805
-57,630
EBIT
-64,387
-62,871
-58,424
Net Income
-58,950
-58,348
-54,365
Net Change In Cash
0
0
5,588
Free Cash Flow
-42,849
-52,599
-44,385
Cash
88,219
215,801
53,229
Basic Shares
99,240
94,804
86,730

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$0
$0
$0
$7,871
Gross Profit
-3,588
-5,878
-147
7,845
EBITDA
-205,860
-141,961
-75,404
-34,569
EBIT
-208,130
-147,839
-75,551
-35,289
Net Income
-192,410
-132,643
-71,806
-66,451
Net Change In Cash
0
0
0
7,871
Cost of Revenue
-79,798
-22,506
204,766
Free Cash Flow
-156,420
-125,501
-60,482
-35,850
Cash
53,229
139,886
219,684
242,190
Basic Shares
79,657
58,739
38,730
11,081

Earnings Calls

Quarter EPS
2024-09-30
-$0.64
2024-06-30
-$0.59
2024-03-31
-$0.62
2023-12-31
-$0.63